Vaccine approved for meningococcal disease in infants and toddlers

Article

Children as young as 9 months can now be immunized for the prevention of meningococcal disease.

Children as young as 9 months now can be immunized for the prevention of invasive meningococcal disease, according to FDA.

Menactra (Sanofi Pasteur; Swiftwater, Pennsylvania) tetravalent conjugate vaccine was first approved in 2005 to protect people aged 2 through 55 years against meningitis caused by Neisseria meningitidis serogroups A, C, Y and W-135. The bacteria invade the bloodstream and the meninges that surround the brain and spinal cord and can cause neurologic problems, coma, and even death.

Between 10% and 15% of patients who develop meningococcal disease die from the infection, and another 10% to 20% develop complications such as brain damage or loss of limbs and hearing.

FDA granted approval for Menactra in this age group after reviewing 4 clinical studies that evaluated the safety of Menactra for children as young as 9 months.

The most common adverse effects reported in children who received the Menactra vaccine were comparable to a control group that received other childhood vaccinations: tenderness at the injection site, fever, and general irritability. Serious adverse events recorded through 6-month follow-up occurred in less than 3% of the children.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Stephanie Anne Deutsch, MD, MS, MSCR, FAAP
Erica Prochaska, MD
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Deborah Persaud, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.